Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (23.9), the stock would be worth ¥-2.42 (128% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -85.1 | ¥8.61 |
0%
|
| Industry Average | 23.9 | ¥-2.42 |
-128%
|
| Country Average | 28.8 | ¥-2.92 |
-134%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693
|
3.6B CNY | -85.1 | -83.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 27.4 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 16.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 15.6 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.4 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Hainan Shuangcheng Pharmaceuticals Co Ltd
Glance View
Hainan Shuangcheng Pharmaceuticals Co Ltd is a compelling narrative of strategic growth rooted in the heart of China's expanding healthcare landscape. Founded amid the tropical allure of Hainan Province, the company has meticulously carved its niche in the pharmaceutical industry, focusing on the development, manufacture, and distribution of a diverse range of healthcare products. Its operations encompass the creation of traditional Chinese medicines, nutraceuticals, and essential drugs that cater to a wide spectrum of therapeutic needs in the market. By leveraging its rich heritage in Chinese herbal medicine, coupled with modern manufacturing techniques, Shuangcheng has cultivated an innovative portfolio that addresses both contemporary health challenges and traditional wellness aspirations. The company generates revenue primarily through its comprehensive product lineup sold across various distribution channels, including hospitals, pharmacies, and third-party distributors throughout China. With a strategic eye on quality and efficacy, Shuangcheng ensures that its products meet rigorous health standards, thereby building trust and credibility among both healthcare professionals and consumers. This dedication to excellence is bolstered by significant investments in research and development, allowing the firm to potentially evolve with changing medical demands and regulatory landscapes. As the healthcare sector grows within China, Hainan Shuangcheng Pharmaceuticals stands poised at the intersection of modern medicine and traditional wisdom, offering solutions that resonate with the needs of its diverse clientele and ensuring a robust financial performance.